Skip to main content

Table 2 Adoptive transfer of CD4 T cells populations into B16-OVA tumor-bearing mice.

From: T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3

Percent Foxp3EGFP Positive Cells Received From Spleen and Tumor
T Cell Subsets Adoptively
Transferred
Spleen
day 5
Tumor
day 5
Spleen
day 10
Tumor
day 10
Spleen
day 15
Tumor
day 15
Bone marrow control
(0%)
0.0, 0.0   0.0, 0.0   0.0, 0.0  
C57BL/6
CD4
(0%)
0.0, 0.0   0.3, 0.5 0.0,0.0 0.0, 0.0  
C57BL/6 nTreg
CD4
(100%)
1.4, 1.9   11.7, 15.2   14.8, 20.8  
C57BL/6 iTreg
CD4
(26%)
0.4, 0.3   4.5, 3.8   0.4, 2.0  
OTII CD4
(0%)
0.0, 0.1   0.0, 0.0   0.0, 0.0 0.0, 0.0
OTII iTreg
CD4
(10.4%)
0.2, 0.0 0.0, 0.0 0.9, 1.4 0.1, 0.1 0.3, 0.4  
  SPLEEN
day 7
TUMOR
day 7
SPLEEN
day 14
TUMOR
day 14
SPLEEN
day 25
TUMOR
day 25
Pmel CD8
(<1%)
0.0, 0.0 0.1, 0.1 0.0, 0.0 0.1, 0.1 0.0, 0.0 0.0,0.0
  1. C57BL/6 (CD45.2) mice bearing (five-day) B16-OVA tumors were irradiated with 900 cGy. The following day, all mice received bone marrow, from syngenic CD45.1 mice. Several different populations of cells were adoptively transferred into B16-OVA tumor-bearing mice. These cells were activated for 72 hours with αCD3/αCD28/IL-2, and in some cases flow-purified to yield a homogenous population of Foxp3EGFP-positive or negative cells. These cell populations included: (1) 105 C57BL/6 CD4 T cells (0% Foxp3EGFP); (2) 105 C57BL/6 CD4 nTreg (100% Foxp3EGFP); (3) 105 C57BL/6 CD4 TGFβ-induced iTreg (flow purified Foxp3EGFP-negative CD4 T cells, activated in the presence of TGFβ for 72 hours to yield ~26% Foxp3EGFP iTreg); (4) 105 OTII CD4 T cells (0% Foxp3EGFP); (5) 105 OTII CD4 iTreg (10.4% Foxp3EGFP); and 106 Pmel CD8 (<1% Foxp3EGFP). When sufficient numbers of TIL could be isolated for flow (at least 103), these were also surface phenotyped.